Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

5.785 -0.085 (-1.45%)
Streaming Delayed Price Updated: 10:08 AM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Why Atai Life Sciences Stock Was So Lively This Week
The company, which focuses on psychedelic-based medicine, had a busy few days on both the regulatory and financing fronts. 
Via The Motley Fool
Market Momentum: A Diverse Group of Stocks Soar to 52-Week Highs Amidst Shifting Tides
As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion sales by 2035. 
Via Benzinga
Alibaba, Lithium Americas And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
 
Via Benzinga
Demystifying ATAI Life Sciences: Insights From 5 Analyst Reviews
 
Via Benzinga
Why Atai Life Sciences Stock Crushed It on Tuesday
Investors cheered good news from the lab delivered by the company. 
Via The Motley Fool
Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients
Atai Life Sciences and Beckley Psytech report strong BPL-003 study results in treatment-resistant depression, with Phase 3 trials expected in 2026. 
Via Benzinga
Cathie Wood's Ark Bets Big On Solana Treasury Play: Makes $162M Investment In Brera Holdings As Stock Explodes 225%
On Thursday, Cathie Wood-led Ark Invest executed significant trades, notably selling shares of Tempus AI Inc (NASDAQ:TEM) and buying shares of Brera Holdings PLC (NASDAQ:BREA), 
Via Benzinga
Topics Artificial Intelligence
Atai Life Sciences Revenue Jumps 163%
Via The Motley Fool
Topics Intellectual Property
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
 
Via Benzinga
Why Is ATAI Life Sciences Stock Trading Lower On Monday?
Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile. 
Via Benzinga
What's going on in today's pre-market session
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Higher As US-EU Ink Trade Deal: Tesla, Palantir, UnitedHealth In Focus
U.S. stock futures rose on Monday after ending higher on Friday. Futures of major benchmark indices were higher. 
Via Benzinga
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga
Top movers in Friday's after hours session
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
 
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Atai and Beckley report that a single dose of BPL-003 reduced depression symptoms significantly and safely in treatment-resistant patients. 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip
The merger focuses on creating a combined company focused on psychedelic mental health therapies. 
Via Stocktwits
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
Atai Life Sciences shares surged 11.4% after Beckley Psytech reported encouraging Phase 2a results of its depression treatment 
Via Stocktwits
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.